Written and maintained by CASRAI Editorial Board
Last updated
ICH M3(R2) is the international harmonized guideline defining the nonclinical safety studies required to justify human clinical trials and marketing authorization for pharmaceuticals. Established to align toxicology, safety pharmacology, and pharmacokinetic standards across global health authorities, the guidance establishes baseline requirements for advancing therapeutic candidates into clinical development.
What it is and who runs it
The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) maintains and governs the ICH M3(R2) guideline. Entitled Guidance on Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals, the document reached Step 4 harmonisation in June 2009. The guideline operates as the global reference standard across major national regulatory authorities, having been formally adopted by the U.S. Food and Drug Administration (FDA) as final guidance in January 2010, the European Medicines Agency (EMA), Japan’s Pharmaceuticals and Medical Devices Agency (PMDA), Health Canada, and Swissmedic.
Understanding what is pharmacology provides the foundational framework for interpreting the pharmacodynamic and pharmacokinetic profiles that ICH M3(R2) standardizes. The core objective of the program is to define the timing and duration of nonclinical safety evaluations relative to clinical trials, ensuring volunteer and patient safety while reducing animal use in accordance with the 3R principles (reduce, refine, replace).
Eligibility and scope
As described on the official page on 2026-11-07, ICH M3(R2) applies to the nonclinical safety evaluation of small-molecule synthetic pharmaceuticals, chemical new chemical entities (NCEs), and therapeutic drug candidates intended for human clinical trials and marketing approval. The scope encompasses all phases of human investigation, from Phase 1 First-in-Human (FIH) trials through post-marketing commitments.
Specific classes of therapeutics are exempted or handled under specialized companion guidelines:
- Biopharmaceuticals and biotechnology-derived products: Recombinant proteins, monoclonal antibodies, and vaccines are governed primarily by ICH S6(R1) rather than the standard M3(R2) toxicology schedule.
- Anticancer pharmaceuticals: Small-molecule agents developed exclusively for patients with advanced, life-threatening malignancies follow ICH S9, which permits accelerated timelines and abbreviated reproductive or chronic toxicology packages.
- Cell and gene therapies: Advanced therapy medicinal products (ATMPs) require customized nonclinical programmes reviewed on a case-by-case basis by regional regulatory authorities.
What it requires
ICH M3(R2) defines mandatory nonclinical modules that sponsors must complete before dosing human subjects in clinical trials or filing for marketing authorization.
Safety pharmacology core battery
Prior to first-in-human administration, sponsors must evaluate the primary vital organ systems through a standardized safety pharmacology battery (governed by ICH S7A and S7B). The core battery mandates assessment of:
- Central nervous system (CNS): Evaluating motor activity, behavioral changes, coordination, and reflex responses (typically assessed via modified Irwin or Functional Observational Battery assays).
- Cardiovascular system: Assessing blood pressure, heart rate, electrocardiogram (ECG) parameters, and in vitro hERG potassium channel inhibition to predict delayed ventricular repolarization (QT interval prolongation).
- Respiratory system: Measuring respiratory rate, tidal volume, and hemoglobin oxygen saturation in conscious animal models.
Repeated-dose toxicity study durations
ICH M3(R2) establishes rigorous minimum durations for repeated-dose toxicity studies in two mammalian species (one rodent, such as rats or mice, and one non-rodent, such as dogs or non-human primates). The nonclinical duration must match or exceed the intended clinical trial duration up to designated regulatory ceilings.
| Maximum clinical trial duration | Rodent study duration (clinical support) | Non-rodent study duration (clinical support) | Marketing authorization requirement |
|---|---|---|---|
| Up to 2 weeks | 2 weeks | 2 weeks | 1 month (rodent) / 1 month (non-rodent) |
| Between 2 weeks and 1 month | 1 month | 1 month | 3 months (rodent) / 3 months (non-rodent) |
| Between 1 month and 3 months | 3 months | 3 months | 6 months (rodent) / 6 months (non-rodent) |
| Between 3 months and 6 months | 6 months | 6 months | 6 months (rodent) / 9 months (non-rodent) |
| Greater than 6 months | 6 months | 9 months | 6 months (rodent) / 9 months (non-rodent) |
Genotoxicity, reproduction, and carcinogenicity
The guidance sets phased milestones for specialized safety evaluations:
- Genotoxicity: A standard battery (in vitro bacterial reverse mutation Ames test, in vitro mammalian chromosomal aberration or mouse lymphoma assay, and an in vivo rodent micronucleus test per ICH S2) must be completed before initiating Phase 1.
- Reproduction toxicity: Characterization of embryo-fetal development and fertility (ICH S5) is required before enrolling women of childbearing potential in clinical trials.
- Carcinogenicity: Two-year rodent bioassays or transgenic mouse assays (ICH S1) are required for pharmaceuticals indicated for continuous administration of at least 6 months, but these studies support the marketing dossier and are rarely required prior to Phase 3 trials.
Application and compliance steps
Complying with ICH M3(R2) requires structured execution of nonclinical programmes that support regulatory filings:
- Nonclinical lead optimization: Screen prospective compounds using chemical bioactivity profiles, referencing datasets such as the PubChem chemistry bioassay data repository and medicinal chemistry literature in the Journal of Medicinal Chemistry.
- Exploratory clinical trial selection (optional): For programs seeking early human pharmacokinetic data, sponsors can select one of five Exploratory Clinical Trial approaches defined in ICH M3(R2). Approach 1 (microdosing) permits administration of a total dose not exceeding 100 µg (and not exceeding 1/100th of the NOAEL and pharmacologically active dose) supported by an extended single-dose toxicity study.
- Formal IND-enabling studies under GLP: Execute pivotal toxicology, safety pharmacology, and toxicokinetic evaluations in full compliance with 21 CFR Part 58 GLP requirements. These comprehensive datasets form the foundation of IND-enabling studies.
- First-in-human starting dose calculation: Calculate safe clinical starting doses based on the No Observed Adverse Effect Level (NOAEL) established in the most sensitive animal species, applying appropriate allometric scaling and safety factors as detailed in the guide on NOAEL first in human dosing.
- Chronic toxicity expansion: Prior to extending clinical dosing beyond 3 or 6 months, initiate 6-month rodent and 9-month non-rodent chronic toxicology studies to support Phase 3 trials and marketing authorization dossiers.
Typical timeline phases
Compliance timelines for ICH M3(R2) follow distinct development phases, aligning nonclinical milestones with human trial gates:
- Phase 1 Enabling (Pre-IND Phase): Completion of the core safety pharmacology battery, acute or 2-week repeated-dose toxicity studies in two mammalian species with toxicokinetics, in vitro and in vivo genotoxicity battery, and initial local tolerance testing.
- Phase 2 Transition Phase: Extension of repeated-dose toxicity study durations to 1 to 3 months to match proposed Phase 2 treatment periods, accompanied by male and female fertility and embryo-fetal developmental toxicity studies.
- Phase 3 and Registration Phase: Completion of chronic toxicity studies (6 months in rodents, 9 months in non-rodents), phototoxicity evaluations, pre- and post-natal development studies, and long-term carcinogenicity bioassays.
Common mistakes
- Misaligning non-rodent study durations across regulatory regions: While the European Union accepts 6-month non-rodent studies under certain conditions, the United States FDA generally requires 9-month non-rodent studies to support clinical trials or marketing authorization lasting longer than 6 months. Failing to conduct 9-month studies creates substantial regulatory risk for global submissions.
- Prematurely initiating 2-year carcinogenicity bioassays: Conducting resource-intensive carcinogenicity studies during early Phase 1 or Phase 2 development risks wasting significant capital if the candidate fails clinical efficacy proof-of-concept.
- Omitting core safety pharmacology before First-in-Human dosing: Relying solely on standard general toxicology observations without dedicated assessments of respiratory, central nervous system, and cardiovascular electrophysiology creates immediate clinical hold grounds during IND review.
- Conflating pharmacology research with clinical pharmacy: Operational distinctions between nonclinical testing and hospital dispensing protocols are examined in the analysis of pharmacy vs pharmacology.
Related programs and guidelines
ICH M3(R2) operates within a broader framework of international nonclinical and regulatory standards. The table below delineates the relationship between M3(R2) and companion guidelines.
| Guideline / Standard | Governing body | Primary scope | Key difference from ICH M3(R2) |
|---|---|---|---|
| ICH S6(R1) | ICH | Preclinical safety evaluation of biotechnology-derived pharmaceuticals | Applies to biologics, proteins, and antibodies; emphasizes species-specific target binding rather than standard two-species rodent/non-rodent requirements |
| ICH S9 | ICH | Nonclinical evaluation for anticancer pharmaceuticals | Permits abbreviated nonclinical programs and shorter chronic toxicology studies for life-threatening advanced cancer indications |
| ICH S7A / S7B | ICH | Safety pharmacology (vital organ systems and ventricular repolarization) | Defines detailed testing methodologies for cardiovascular, respiratory, and CNS endpoints referenced by M3(R2) |
| 21 CFR Part 58 | U.S. FDA | Good Laboratory Practice (GLP) for nonclinical laboratory studies | Codifies U.S. federal quality assurance, facility, and record-keeping requirements for studies supporting regulatory filings |
Frequently asked questions
What is the primary difference between ICH M3(R1) and ICH M3(R2)?
ICH M3(R2), finalized in 2009, revised the original 1997 guidance by standardizing high-dose selection criteria, introducing five formal approaches for Exploratory Clinical Trials (including microdosing), updating requirements for non-rodent chronic toxicity study durations, and refining recommendations for the inclusion of women in clinical trials.
What are the minimum repeated-dose toxicity study durations to support Phase 1 trials?
For Phase 1 clinical trials lasting up to 2 weeks, ICH M3(R2) requires a minimum of 2 weeks of repeated-dose toxicity studies in two mammalian species (one rodent and one non-rodent). In the United States, an extended single-dose toxicity study can support single-dose First-in-Human clinical trials.
Are carcinogenicity studies required prior to Phase 1 clinical trials under ICH M3(R2)?
No. Carcinogenicity studies are not required prior to Phase 1 clinical trials. They are required to support marketing authorization for pharmaceuticals indicated for continuous administration of at least 6 months, and they are typically conducted concurrently with Phase 3 clinical development.
Sources
- International Council for Harmonisation (ICH). “M3(R2) Guideline: Guidance on Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals.” Step 4 Version, dated 11 June 2009. Accessed 2026-11-07. https://database.ich.org/sites/default/files/M3_R2__Guideline.pdf
- U.S. Food and Drug Administration (FDA). “M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals: Guidance for Industry.” Docket FDA-2009-D-0008, January 2010. Accessed 2026-11-07. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/m3r2-nonclinical-safety-studies-conduct-human-clinical-trials-and-marketing-authorization
- European Medicines Agency (EMA). “ICH guideline M3(R2) on non-clinical safety studies for the conduct of human clinical trials and marketing authorisation for pharmaceuticals.” Reference CPMP/ICH/286/1995, December 2009. Accessed 2026-11-07. https://www.ema.europa.eu/en/ich-m3-r2-non-clinical-safety-studies-conduct-human-clinical-trials-pharmaceuticals-scientific-guideline
